Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes
2018 ◽
Vol 35
(5)
◽
pp. 793-804
◽
Keyword(s):
Keyword(s):
2017 ◽
Vol 20
(4)
◽
pp. 831-839
◽
2018 ◽
Vol 130
(4)
◽
pp. 375-380
◽
Keyword(s):
2020 ◽
Vol 19
(10)
◽
pp. 2213-2217
2019 ◽
Vol 21
(9)
◽
pp. 2133-2141
◽
Keyword(s):
2017 ◽
Vol 129
(4)
◽
pp. 436-445
◽
Keyword(s):